Restless legs syndrome

CMAJ. 2017 Feb 13;189(6):E245. doi: 10.1503/cmaj.160527.

Authors

Philippe Rizek¹, Niraj Kumar²

Affiliations

¹ Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, Ont. philippe.rizek@trilliumhealthpartners.ca.
² Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, Ont.

No abstract available

MeSH terms

Anemia / epidemiology
Anticonvulsants / therapeutic use*
Caffeine / adverse effects
Central Nervous System Depressants / adverse effects
Central Nervous System Stimulants / adverse effects
Cognitive Behavioral Therapy*
Disease Progression
Dopamine Agonists / therapeutic use*
Ethanol / adverse effects
Exercise Therapy*
Humans
Renal Insufficiency, Chronic / epidemiology
Restless Legs Syndrome / chemically induced
Restless Legs Syndrome / epidemiology
Restless Legs Syndrome / therapy*
Sleep Hygiene

Substances

Anticonvulsants
Central Nervous System Depressants
Central Nervous System Stimulants
Dopamine Agonists
Caffeine
Ethanol